Blog
RSS FeedPosted by Michael Wonder on 09 Dec 2019
Base drug prices on value rather than R&D
8 December 2019 - For decades, R&D spending on pharmaceuticals has gone up more or less in tandem with the ...
Posted by Michael Wonder on 26 Nov 2019
Using GRADE methodology to assess innovation of new medicinal products in Italy
25 November 2019 - In April 2017 the Italian Medicine Agency developed new criteria to grant any new medicinal product with ...
Posted by Michael Wonder on 22 Nov 2019
The life improvement value: a new measure of cost-efficiency
23 November 2019 - The decision not to make zoster vaccination available to people older than 79 years1 was based on ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 05 Nov 2019
Obscure model puts a price on good health—and drives down drug costs
4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...
Posted by Michael Wonder on 01 Nov 2019
Report clearly demonstrates the value of vaccines
1 November 2019 - Medicines Australia welcomes today’s report from the Australian Institute of Health and Welfare which verifies the ...
Posted by Michael Wonder on 17 Oct 2019
Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines
17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who ...
Posted by Michael Wonder on 17 Oct 2019
Some say a non-profit research group unfairly influences drug prices
16 October 2019 - Have you ever wondered how pharmaceutical companies decide whether that pill you take costs $3 or ...
Posted by Michael Wonder on 15 Oct 2019
Accounting for hope: using ‘mean survival gain’ to price new cancer drugs
14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...
Posted by Michael Wonder on 14 Oct 2019
'Veiled in secrecy': call for surgeons to disclose complications rates
14 October 2019 - Surgeons are being urged to disclose their rates of surgical complications to prove they're worth the ...
Posted by Michael Wonder on 10 Oct 2019
PhRMA Foundation partners with National Health Council to host first of its kind conference on new approaches to value assessment
10 October 2019 - The PhRMA Foundation and the National Health Council will host The Next Generation of Value Assessment: ...
Posted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 05 Sep 2019
What is the value of market-wide health care price transparency?
5 September 2019 - A primary driver of high spending in the US health care system, relative to other countries, ...
Posted by Michael Wonder on 15 Aug 2019
ICER's value framework and patient feedback: Q&A with Steve Pearson
15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...